Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report released on Saturday.

A number of other brokerages have also recently issued reports on SUPN. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $62.83.

Supernus Pharmaceuticals Trading Down 1.2%

NASDAQ SUPN opened at $47.07 on Friday. Supernus Pharmaceuticals has a 12 month low of $40.32 and a 12 month high of $59.68. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -24.52, a PEG ratio of 0.78 and a beta of 0.56. The company’s 50 day moving average is $46.21 and its two-hundred day moving average is $48.90.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Rockefeller Capital Management L.P. grew its holdings in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares during the last quarter. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $49,000. EverSource Wealth Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth approximately $51,000. Hantz Financial Services Inc. lifted its stake in shares of Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 458 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at $55,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.